Pramipexole as adjunct to haloperidol in schizophrenia. Safety and efficacy

European Neuropsychopharmacology

Volumn 7, Issue 1, 1997, Pages 65-70

  Kasper, S ^a   Barnas, C ^a   Heiden, A ^a   Volz, H P ^b   Laakmann, G ^c   Zeit, H ^d   Pfolz, H ^e  

^a UNIVERSITY OF VIENNA   (Austria)

^b FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^c UNIVERSITY OF MUNICH   (Germany)

^d Evangelical Hospital   (Germany)

^e Hospital Baumgartner Hohe   (Austria)

Author keywords

negative symptoms; pramipexole; presynaptic dopamine autoreceptor agonists; schizophrenia

Indexed keywords

DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; HALOPERIDOL; PRAMIPEXOLE;

ADULT; ARTICLE; CLINICAL TRIAL; DRUG COMBINATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SCHIZOPHRENIA;

ADULT; AKATHISIA, DRUG-INDUCED; ANTIPSYCHOTIC AGENTS; BENZOTHIAZOLES; DOPAMINE AGONISTS; DRUG THERAPY, COMBINATION; DYSKINESIA, DRUG-INDUCED; FEMALE; HALOPERIDOL; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; THIAZOLES;

EID: 0030975281     PISSN: 0924977X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-977X(96)00393-8     Document Type: Article

References (23)

1. American Psychiatric Association, Diagnostic and Statistical Manual of Mental Disorders (Third edition, revised) DSM-III-R. (1987) The American Psychiatric Association, Washington D.C.
2. Benkert, O., Gründer, G. and Wetzel, H. (1992) Dopamine autoreceptor agonists in the treatment of schizophrenia and major depression. Pharmacopsychiatry 25, 254-260.
3. Buchsbaum, M.S., Nuechterlein, K.H., Haier, R.J., Wu, J., Sicotte, N., Hazlett, E., Asarnow, R., Potkin, S. and Guich, S. (1990) Glucose metabolic rate in normals and schizophrenics during the continuous performance test assessed by positron emission tomography. Br. J. Psychiatry 156, 216-227.
4. Chouinard, G. and Jones, B.D. (1979) Evidence of brain dopamine deficiency in schizophrenia. Can. J. Psychiatry 24, 661-667.
5. Fleischhacker, W.W., Bergmann, K.J., Perovich, R., Pestreich, L.K., Borenstein, M., Lieberman, J.A. and Kane, J.M. (1989) The Hillside Akathisia Scale: A new rating instrument for neuroleptic-induced akathisia. Psychopharmacol. Bull. 2, 222-226.
6. Ingvar, D.H. and Franzen, G. (1974) Abnormalities of cerebral blood flow distribution in patients with chronic schizophrenia. Acta Psychiatr. Scand. 50, 425-462.
7. Kasper, S., Fuger, J., Zinner, H.J., Bäuml, J. and Möller H.J. (1992) Early clinical results with the neuroleptic roxindole (EMD 49980) in the treatment of schizophrenia - an open study. Eur. Neuropsychopharmacol. 2, 91-95.
8. Kay, S.R., Opler, L.A. and Lindermayer, J.P. (1988) Reliability and validity of the Positive and Negative Syndrome Scale for schizophrenics. Psychiatry Res. 23, 99-110.
9. Kissling, W., Mackert, A., Bäuml, J. and Lauter, H. (1992) Erste klinische Erfahrungen mit dem neuen Dopamin-Autorezeptoragonisten SND 919. In: Gaebel, W and Laux, G. (Eds.) Biologische Psychiatrie. Synopsis 90/91. Springer, Berlin, pp. 256-249.
10. Leblanc, G., Cormier, H.J., Vaillancourt, S., Gagne, M.A. and Gingras, C. (1990) Who are the patients treated in an outpatient clinic with high dosage neuroleptics? Can. J. Psychiatry 35 (1), 12-24.
11. Lecrubier, Y., Puech, A.J., Simon, P. and Widlöcher, D. (1980) Schizophrénie: hyper ou hypofonctionnement du systéme dopaminergique? Une hypothése bipolaire. Psychol. Med. 12, 2431-2441.
12. MacKay, A.V.P. (1980) Positive and negative schizophrenic symptoms and the role of dopamine. Br. J. Psychiatry 137, 379-383.
13. McEvoy, J.P., Hogarty, G.E. and Steingard, S. (1991) Optimal dose of neuroleptic in acute schizophrenia. A controlled study of the neuroleptic threshold and higher haloperidol dose. Arch. Gen. Psychiatry 48, 739-745.
14. Meltzer, H.Y. (1980) Relevance of dopamine autoreceptors for psychiatry: preclinical and clinical studies. Schizophr. Bull. 6, 456-475.
15. National Institute of Mental Health. Clinical Global Impressions (1976). In: Guy, W. (Ed.) ECDEU Assessment Manual for Psychopharmacology, revised edition, Rockville, MD, pp. 217-222.
16. Ohmori, T., Koyama, T., Inoue, T., Matsubara, S. and Yamashita, I. (1993) B-HT 920, a dopamine D2 agonist, in the treatment of negative symptoms of chronic schizophrenia. Biol. Psychiatry 33, 687-693.
17. Olbrich, R. and Schanz, H. (1988) The effect of the partial dopamine terguride on negative symptoms in schizophrenics. Pharmacopsychiatry 21, 389-390.
18. Palluk, R. (1995) Cardiovascular interactions of pramipexole and haloperidol after IV and SC administration in anaesthetised rabbits. Boehringer Ingelheim, U 95-2199, October 17, 1995.
19. Schaefer, E., Bailey, P.E. and Koester, J. (1993) Double-blind, controlled clinical trial to compare the efficacy and tolerance of pramipexole and placebo in patients with residual schizophrenia. Boehringer Ingelheim, U 93-0608, June 25, 1993.
20. Simpson, G.H. and Angus, G.S.W. (1970) A rating scale for extrapyramidal side effects. Acta Psychiatr. Scand. 212 (suppl.), 11-19.
21. Tamminga, C.A., Schaffer, M.H. and Schmith, R.C. (1978) Schizophrenic symptoms improve with apomorphine. Science 200, 567-568.
22. Weinberger, D.R., Bermann, K.F. and Zee, R.F. (1986) Physiological dysfunction of dorsolateral prefontal cortex in schizophrenia: (I) Regional cerebral blood flow (RCBF) evidence. Arch. Gen. Psychiatry 43, 114-124.
23. White, F.J. and Wang, R.Y. (1984) AlO dopamine neurones: role of autoreceptors in determining firing rate and sensitivity to dopamine agonists. Life Sci. 34, 1161-1170.